Sildenafil (SDN) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-209-Ag01	BSA-Sildenafil (SDN)	756
GMP-SMT-209-Ag02	OVA-Sildenafil (SDN)	756
GMP-SMT-209-Ab01	Anti-human Sildenafil (SDN) mouse monoclonal antibody (mAb)	1953
GMP-SMT-209-Ab02	Anti-human Sildenafil (SDN) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-209-Ag01
Product Name	BSA-Sildenafil (SDN)
Target/Biomarker	Sildenafil(SDN)
Expression platform	Synthetic
Bioactivity validation	Sildenafil (SDN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in SDN level test of Cardiovascular disease (Erectile dysfunction) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Sildenafil (SDN) / OVA-Sildenafil (SDN) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-209-Ag02
Product Name	OVA-Sildenafil (SDN)
Target/Biomarker	Sildenafil(SDN)
Expression platform	Synthetic
Bioactivity validation	Sildenafil (SDN) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in SDN level test of Cardiovascular disease (Erectile dysfunction) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Sildenafil (SDN) / OVA-Sildenafil (SDN) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-209-Ab01
Product Name	Anti-human Sildenafil (SDN) mouse monoclonal antibody (mAb)
Target/Biomarker	Sildenafil(SDN)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human Sildenafil (SDN) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Sildenafil (SDN) antibodies in SDN level test of Cardiovascular disease (Erectile dysfunction) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Sildenafil (SDN) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-209-Ab02
Product Name	Anti-human Sildenafil (SDN) human monoclonal antibody (mAb)
Target/Biomarker	Sildenafil(SDN)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Human Sildenafil (SDN) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Sildenafil (SDN) antibodies in SDN level test of Cardiovascular disease (Erectile dysfunction) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Sildenafil (SDN) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. Sildenafil: A Comprehensive Exploration in In Vitro Diagnosis (IVD) Sildenafil, a prominent pharmaceutical compound, has garnered widespread recognition for its therapeutic applications, particularly in addressing conditions such as erectile dysfunction and pulmonary arterial hypertension. Its pharmacological prowess lies in its potent inhibition of phosphodiesterase type 5 (PDE5), resulting in the relaxation of blood vessels and the subsequent improvement of blood circulation. This mechanism underpins its efficacy in facilitating erections and alleviating pulmonary hypertension. In the realm of in vitro diagnosis (IVD), Sildenafil plays a pivotal role as a target molecule for diagnostic assays. Our esteemed biopharmaceutical enterprise specializes in the provision of anti-Sildenafil antibodies and an extensive range of small molecule competitive antigens. This diverse portfolio encompasses an array of variants, including Carrier-coupled antigens, immunogens, hapten-carrier conjugates, BSA-conjugated, and OVA-conjugated forms. Each component within this meticulously engineered collection is designed with precision to facilitate the development of advanced diagnostic assays, enabling the accurate, sensitive, and reliable quantification of Sildenafil levels within diverse biological samples. 2. The Multifaceted Significance of Sildenafil Measurement The measurement of Sildenafil holds profound importance across various domains, spanning clinical therapeutics, patient care, research, and drug development: a. Optimizing Therapeutic Efficacy: Sildenafil is prescribed to individuals grappling with conditions like erectile dysfunction and pulmonary arterial hypertension. Accurate measurement of Sildenafil levels is instrumental in ensuring that patients receive the appropriate dosage, thereby optimizing therapeutic response and enhancing patient well-being. b. Facilitating Treatment Monitoring: Continuous monitoring of Sildenafil levels empowers healthcare practitioners to assess treatment progress and make requisite adjustments. This approach strives for optimal therapeutic outcomes while mitigating potential side effects, ultimately enhancing patient care. c. Enhancing Safety and Compliance: Precise measurement of Sildenafil attests to patient adherence to prescribed medication regimens. It enhances treatment compliance and minimizes the likelihood of adverse events, ensuring patient safety remains paramount. d. Enabling Scientific Exploration: Beyond its clinical utility, Sildenafil measurement significantly contributes to the realm of scientific research and drug development. It serves as a linchpin in elucidating the pharmacokinetics, metabolic pathways, and prospective applications of Sildenafil beyond its established therapeutic indications. This knowledge fuels innovation and drives the development of new therapeutic interventions. e. Point-of-Care Diagnostics: In the context of point-of-care testing (POCT), accurate Sildenafil measurement can be pivotal. It empowers healthcare professionals to make real-time clinical decisions, especially in situations where immediate assessment is critical. In conclusion, the precision in measuring Sildenafil levels within the context of in vitro diagnosis (IVD) emerges as an indispensable and multifaceted facet of healthcare and scientific exploration. This precision profoundly impacts therapeutic efficacy, facilitates treatment monitoring, bolsters patient safety, and fuels scientific innovation. Our specialized product portfolio, meticulously tailored for Sildenafil assessment, stands as a cornerstone in enabling accurate and sensitive quantification of this pharmaceutical compound. By doing so, it not only advances patient care and elevates safety standards but also contributes to the ongoing progress in pharmacology and therapeutic development, ushering in new horizons for healthcare and medical research.

About GDU